[177Lu]Lu-DOTA-TATE在生长抑素受体阳性胃肠胰神经内分泌肿瘤或嗜铬细胞瘤与副神经节瘤青少年患者中的安全性与剂量学:II期NETTER-P研究主要分析
NETTER-P是一项开放标签II期研究,评估177Lu-DOTATATE在12-17岁晚期生长抑素受体阳性高分化1/2级胃肠胰神经内分泌肿瘤或嗜铬细胞瘤与副神经节瘤青少年中的安全性与剂量学。11例患者接受至少1次给药,最常见不良事件为淋巴细胞减少/淋巴细胞计数降低和头痛,未观察到治疗相关肾毒性;肾脏和骨髓累积吸收剂量预测值在青少年和成人安全阈值内,药代动力学两者相当。结论认为与成人胃肠胰神经内分泌肿瘤相比,青少年中未发现177Lu-DOTATATE相关的新安全性信号,长期随访正在进行。
要点
- 11例青少年(4例GEP-NET,7例PPGL)接受177Lu-DOTATATE,中位累积给药活度28.2 GBq。
- 第1周期最常见不良事件为淋巴细胞减少/淋巴细胞计数降低和头痛(各4/11,36%)。
- 治疗期间最常见不良事件为淋巴细胞减少/淋巴细胞计数降低(7/11,64%;≥3级5/11,45%)。
核心结论
- 与成人GEP-NET相比,青少年GEP-NET或PPGL患者中未发现可归因于177Lu-DOTATATE的新安全性信号;长期随访正在进行。
研究设计与样本
- NETTER-P为开放标签II期研究,纳入12-17岁晚期生长抑素受体阳性高分化1/2级GEP-NET或PPGL患者。
- 患者接受4个周期177Lu-DOTATATE,每次7.4 GBq,每8±1周一次,累积计划给药活度29.6 GBq。
- 主要终点为首次给药后肾脏和骨髓吸收剂量及安全性;同时评估治疗期间安全性及青少年与历史成人患者剂量学和药代动力学比较。
主要发现
- 共11例患者入组并接受至少1次177Lu-DOTATATE给药(4例GEP-NET,7例PPGL;中位年龄15岁,范围13-17岁)。
- 中位(范围)累积给药活度为28.2(7.3-29.9)GBq。
- 第1周期最常见不良事件为淋巴细胞减少/淋巴细胞计数降低和头痛,各4/11(36%);第1周期≥3级不良事件发生于4/11(36%)患者。
- 治疗期间最常见不良事件为淋巴细胞减少/淋巴细胞计数降低(7/11,64%;≥3级5/11,45%)。
- 未观察到对安全性生物标志物有临床意义的影响,也未观察到治疗相关肾毒性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: NETTER-P, an open-label Phase II study, evaluated the safety and dosimetry of [177Lu]Lu-DOTA-TATE (hereafter 177Lu-DOTATATE) in adolescents with advanced, somatostatin receptor-positive, well-differentiated, Grade 1/2 gastroenteropancreatic neuroendocrine tumours (GEP-NET) or pheochromocytoma and paragangliomas (PPGL). METHODS: Patients (12-17 years old) received four cycles of 177Lu-DOTATATE (7.4 GBq every 8 ± 1 weeks; cumulative administered activity: 29.6 GBq). Primary endpoints were absorbed dose (kidneys and bone marrow) and safety after first administration. Safety during treatment and comparative assessments of dosimetry and pharmacokinetics between adolescents and historical adult patients were evaluated. RESULTS: Eleven patients (4 GEP-NET, 7 PPGL; median age 15 [range, 13-17] years) were enrolled and received ≥ 1 administration of 177Lu-DOTATATE. Median (range) cumulative administered activity was 28.2 (7.3-29.9) GBq. Lymphopenia/lymphocyte count decreased and headache were the most common adverse events (AEs) during Cycle 1 (each 4/11 [36%]). Cycle 1 Grade ≥ 3 AEs occurred in 4/11 patients (36%). During the treatment period, the most common AE was lymphopenia/lymphocyte count decreased (7/11 [64%]; Grade ≥ 3, 5/11 [45%]). No clinically meaningful impacts on safety biomarkers nor any treatment-related nephrotoxicities were observed. Projected median (range) cumulative absorbed doses (four administrations) were 21 (14-40) Gy in kidneys and 0.76 (0.55-1.0) Gy in bone marrow (using blood data). Dosimetry values were predicted to be within safety thresholds for adolescents and adults; pharmacokinetics were comparable in both populations. CONCLUSION: No new safety signals attributable to 177Lu-DOTATATE were identified in adolescents with GEP-NET or PPGL versus adults with GEP-NET. Long-term follow-up is ongoing. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04711135. Registered 15 January 2021.
引用
- Gaze MN, Handkiewicz-Junak D, Hladun R, et al. Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study. Eur J Nucl Med Mol Imaging. 2025. PMID: 40198358. doi:10.1007/s00259-025-07246-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。